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Administering polymyxin antibiotics in a traditional fashionmay be ineffective against Gram-negative ESKAPE (Enterococcus
faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter
species) pathogens. Here, we explored increasing the dose intensity of polymyxin B against two strains of Acinetobacter bau-
mannii in the hollow-fiber infectionmodel. The following dosage regimens were simulated for polymyxin B (t1/2 8 h): non-
loading dose (1.43 mg/kg of body weight every 12 h [q12h]), loading dose (2.22 mg/kg q12h for 1 dose and then 1.43 mg/kg q12h),
front-loading dose (3.33 mg/kg q12h for 1 dose followed by 1.43 mg/kg q12h), burst (5.53 mg/kg for 1 dose), and supraburst (18.4
mg/kg for 1 dose). Against both A. baumannii isolates, a rapid initial decline in the total population was observed within the first
6 h of polymyxin exposure, whereby greater polymyxin B exposure resulted in greater maximal killing of1.25,1.43,2.84,
2.84, and3.40 log10 CFU/ml within the first 6 h. Unexpectedly, we observed a paradoxical effect whereby higher polymyxin B
exposures dramatically increased resistant subpopulations that grew on agar containing up to 10 mg/liter of polymyxin B over
336 h. High drug exposure also proliferated polymyxin-dependent growth. A cost-benefit pharmacokinetic/pharmacodynamic
relationship between 24-h killing and 336-h resistance was explored. The intersecting point, where the benefit of bacterial killing
was equal to the cost of resistance, was an fAUC0–24 (area under the concentration-time curve from 0 to 24 h for the free, un-
bound fraction of drug) of 38.5 mg · h/liter for polymyxin B. Increasing the dose intensity of polymyxin B resulted in amplifica-
tion of resistance, highlighting the need to utilize polymyxins as part of a combination against high-bacterial-density A. bau-
mannii infections.
The polymyxin antibiotics have emerged as a last line of defensefor the treatment of Gram-negative strains resistant to all
other currently available antibiotics (1–3). Polymyxin B and colis-
tin are often the only available agents with activity against these
Gram-negative superbugs (4, 5). Even more worrisome is the first
report of plasmid-mediated polymyxin resistance in Escherichia
coli, which could be transferred to other Gram-negative strains
(6). Furthermore, current dosage regimens for both polymyxin B
and colistin result in polymyxin plasma concentrations that are
suboptimal in a significant proportion of patients (7–10). In vitro
and animal studies clearly demonstrate that antibiotic resistance is
amplified during exposure to suboptimal polymyxin concentra-
tions, especially against polymyxin-heteroresistant strains that are
frequently isolated in Acinetobacter baumannii (11–14).
Administering nontraditional, high-intensity polymyxin regi-
mens may be a strategy to maximize bacterial killing while mini-
mizing resistance and potential toxicity. We have previously de-
termined that front-loading colistin resulted in greater bacterial
killing within the first 24 h against Pseudomonas aeruginosa (15).
The polymyxins are suitable candidates for high-intensity expo-
sure at the beginning of therapy due to their rapid bactericidal
activity against high bacterial densities (16). However, high-inten-
sity regimens for polymyxin B have not been evaluated against A.
baumannii. To date, there have been no studies that profiled the
time course of A. baumannii responses to polymyxin B over long-
term durations at high bacterial densities that correspond to in-
fections such as ventilator-associated pneumonia (VAP) (17, 18).
In the present study, we explored how increasing the dose in-
tensity of polymyxin B influences bactericidal activity and resis-
tance suppression against A. baumannii. A hollow-fiber infection
model (HFIM) was used to simulate a range for polymyxin B
varying in initial dose intensity. Bacterial killing and detailed pop-
ulation analysis profiles that tracked the amplification of resis-
tance over a 14-day period were evaluated.
MATERIALS AND METHODS
Bacterial isolates, antibiotics, and susceptibility testing. Two A. bau-
mannii strains were utilized, ATCC 19606 and 03-149.01. ATCC 19606
was selected as a laboratory control isolate. 03-149.01 was from a patient
enrolled in an open-label population pharmacokinetic study who re-
ceived colistin methanesulfonate as part of his or her clinical care for
treatment of a bloodstream infection or pneumonia due to a Gram-neg-
ative bacillus (9). Neither isolate was previously exposed to polymyxin
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B or colistin. Analytical-grade polymyxin B was purchased from Sig-
ma-Aldrich (lot WXBB4470V; St. Louis, MO). Fresh stock solutions of
polymyxin B were prepared immediately prior to each experiment. Cat-
ion-adjusted Mueller-Hinton broth (CAMHB) (Difco, Detroit, MI, USA)
supplemented with calcium (25 mg/liter) and magnesium (12.5 mg/liter)
was used as the growth medium. MIC values were determined in quadru-
plicate according to the CLSI guidelines. Both strains had a polymyxin B
MIC of 0.5 mg/liter.
HFIM. The HFIM was used to simulate the time course of unbound
plasma concentrations observed in patients receiving polymyxin B regi-
mens by using an approach that was previously described (19, 20). Cellu-
losic hollow-fiber cartridges (C3008; Fiber Cell Systems, Fredrick, MD)
were utilized in all experiments, and samples were serially collected for
336 h. Total population counts were quantified by depositing appropri-
ately diluted bacterial samples on Mueller-Hinton agar (MHA) plates. In
addition, population analysis profiles (PAP) were performed by plating
diluted samples onto MHA plates containing polymyxin B at 0.5, 1, 2, 3, 4,
6, 8, or 10 mg/liter to track resistant subpopulations over 336 h.
Dosage regimens were simulated for polymyxin B (t1/2 8 h) using a
protein binding level of 42%, based on the population pharmacokinetic
model by Sandri et al. (7, 8), from 24 adult patients that received physi-
cian-selected, intravenous polymyxin B dosage regimens ranging from
0.45 to 3.38 mg/kg/day. Of the 24 patients participating in the population
pharmacokinetic study, 23 patients received the drug every 12 h and 1
patient received polymyxin B every 24 h. The following resultant
fAUC0 –24 (area under the concentration-time curve from 0 to 24 h for the
free, unbound fraction of drug) values were determined: range of 6.2 to
53.5 mg · h/liter, median of 26.5 mg · h/liter, average of 29.4 mg · h/liter,
and standard deviations of 10.4 mg · h/liter, as shown in Fig. 1 (7). The
maximum fAUC over 24 h at steady state was 60.4 mg · h/liter. There were
5 regimens simulated in the HFIM: regimen 1, polymyxin B non-
loading dose (1.43 mg/kg every 12 h [q12h], generating an fAUC0 –24 of
28.9 mg · h/liter across the first day and an fAUC at steady state [fAUCss]
of 35.9 mg · h/liter); regimen 2, polymyxin B with loading dose (2.22
mg/kg for 1 dose followed by 1.43 mg/kg q12h starting 12 h later,
fAUC0 –24 of 35.9 mg · h/liter across each day); regimen 3, polymyxin B
front-loading dose (3.33 mg/kg for 1 dose followed by 1.43 mg/kg q12h
starting 12 h later, with an fAUC0 –24 of 48.2 mg · h/liter across the first
day and an fAUCss of 35.9 mg · h/liter at steady state); regimen 4,
polymyxin B burst (5.53 mg/kg for 1 dose followed by no subsequent
doses, with an fAUC0 –24 of 60.4 mg · h/liter); and regimen 5, polymyxin
B supraburst (18.4 mg/kg for 1 dose followed by no subsequent doses,
with an fAUC0 –24 h of 202.5 mg · h/liter).
Four of the above-described regimens (non-loading dose [regimen 1],
loading dose [2], front loading [3], and burst [4]) were in the range of the
achieved fAUCs in critically ill patients from the population pharmacoki-
netic study of polymyxin B (7). Regimens 1 to 3 were administered across
the 14-day HFIM study, while regimens 4 and 5 were administered as
single-dose regimens given only on day 1. At steady state, the highest
fAUC over 24 h achieved in critically ill patients was 60.4 mg · h/liter,
which provided the rationale for simulating the polymyxin B burst regi-
men (regimen 4) that was administered as a single dose. Regimen 5, su-
praburst, was selected as a supratherapeutic proof-of-concept regimen to
test the hypothesis that high-intensity regimens resulted in the amplifica-
tion of resistance. The rationale for both of these regimens was to leverage
the rapid, concentration-dependent, bactericidal activity of the poly-
myxin antibiotics at the beginning of therapy while decreasing potential
exposure. Characterizing the pharmacodynamics of these new polymyxin
regimens will be beneficial in defining how to optimally administer poly-
myxin B in combination with other antibiotics in the future. Polymyxin B
concentrations were quantified using validated high-performance liquid
chromatography-tandem mass spectrometry (LC-MS/MS) as previously
described (21), with good reproducibility (coefficients of variation of
9.0%) and accuracy (observed concentrations were10% from target
concentrations). The limit of quantification was 0.1 mg/liter.
Cost-benefit PK/PD analyses. To determine the pharmacokinetic/
pharmacodynamic (PK/PD) relationship between exposure and bacterial
killing and resistance, we utilized a cost-benefit approach. We defined the
benefit as initial bacterial killing of the total population within the first 24
h and cost as the amplification of resistant subpopulations which included
real-time PAP data over 336 h. An area-based integrated PK/PD measure
was utilized as previously described (22). Using the linear trapezoid rule,
the area under the CFU curve for the total population over 24 h
(AUCFU0 –24) was calculated to assess bacterial killing. The 24-h log
ratio area for bacterial killing then was calculated as the logarithm of
the AUCFU0 –24 of the total population (AUCFUdrug total population) di-
vided by the AUCFU0 –24 of the total population for the growth control
(AUCFUcontrol), as described in equation 1. The AUCFU of resistant sub-
populations was also calculated over 336 h (AUCFUresistant subpopulation)
and normalized by the AUCFU over 336 h of the total population
(AUCFUtotal population) to generate the 336-h log ratio area, a measure of
resistance amplification (equation 2). For each polymyxin B regimen, five
resistant subpopulations were used in the resistance analysis that were
obtained from bacterial counts on agar containing 3, 4, 6, 8, and 10 mg/
liter of polymyxin B (the CLSI breakpoint for polymyxin resistance is2
mg/liter).
24-h log ratio areabacterial killing log10AUCFUdrug total populationAUCFUcontrol 
(1)
336-h log ratio arearesistant subpopulation
 log10AUCFUresistant subpopulationAUCFUtotal population  (2)
E E0
Emax  fAUC24H
EC50H fAUC24H
(3)
A four-parameter Hill-type model (equation 3) was fit to the effect
parameter using Systat (version 12; Systat Software Inc., San Jose, CA)
(22). In this model,E (dependent variable) represents the log ratio area,E0
is the effect at a polymyxin B fAUC24 of 0, Emax is the maximum effect of
FIG 1 fAUCs over 0 to 24 h for polymyxin B for each of the 24 critically ill
adult patients are shown and are based on the population pharmacokinetic
model by Sandri et al. (7, 8). All patients received physician-selected, intrave-
nous polymyxin B regimens ranging from 0.45 to 3.38 mg/kg/day. The result-
ing fAUCs are shown for each patient. In the previous population pharmaco-
kinetic study, there were 23 patients who received the drug every 12 h and 1
patient who received polymyxin B every 24 h. The fAUC (0 to 24 h) ranged
from 6.2 to 53.5 mg · h/liter with a median of 26.5 mg · h/liter, average of 29.4
mg · h/liter, and standard deviation of 10.4 mg · h/liter. The maximum fAUC
over 24 h at steady state was 60.4 mg · h/liter. These data served as the basis for
the simulated regimens to be studied in the hollow-fiber infection model.
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the polymyxin B regimen, fAUC24 is the free polymyxin B area under the
curve within the first 24 h, EC50 is the polymyxin B fAUC24 displaying
50% of the maximum effect, and H is the sigmoidicity constant.
RESULTS
The antibiotic activities of the simulated polymyxin B regimens
against A. baumannii ATCC 19606 (Fig. 2) and 03-149.01 (Fig. 3)
were determined over 336 h. With all regimens against both iso-
lates, there was a rapid initial decline in which the reductions in
the total population occurred very early in therapy, within the first
2 to 6 h of polymyxin exposure. Greater polymyxin B exposure
across the first day resulted in larger maximal log reductions in
bacterial counts from the baseline for both ATCC 19606 for regi-
mens 1, 2, 3, 4, and 5 (1.17, 1.43, 2.84, 3.40, and 1.96,
respectively) and the 03-149.01 isolate (1.25, 1.30, 2.10,
2.82, and 2.54, respectively) within the first 6 h. The rapid
initial bactericidal activity that was present in the first 6 h was
followed by the regrowth of the total population by 24 h for both
isolates, although the degree of regrowth varied between the two
isolates. For ATCC 19606, regrowth occurred within 24 h for all
polymyxin B regimens, after which counts were uniformly stable
up to 336 h. For 03-149.01, regrowth occurred rapidly for lower-
intensity regimens (non-loading dose and loading dose) and was
delayed for high-intensity regimens (front-loading, burst, and su-
praburst).
The polymyxin-resistant subpopulations detected over 336 h
are shown in Fig. 4 for ATCC 19606 and Fig. 5 for 03-149.01. The
non-loading dose regimens amplified resistant subpopulations at
24 h, resulting in resistant subpopulations that were major com-
ponents of the overall population. The amplification observed
within the first 24 h was driven by drug exposure, with higher-
initial-exposure polymyxin regimens conferring higher levels of
resistance. For resistant subpopulations, greater drug exposure
also resulted in polymyxin-dependent growth: higher bacterial
counts were noted on polymyxin-containing agar than on drug-
free agar. This phenomenon was particularly evident whenA. bau-
mannii bacteria were exposed to high-intensity regimens (front-
loading, burst, and supraburst) and was more pronounced in the
clinical A. baumannii isolate 03-149.01 than in the ATCC isolate.
The population analysis profiles (PAPs) resulting from the
simulated polymyxin B regimens are shown in Fig. 6 for A. bau-
mannii 03-149-1. After 24 h of drug exposure in the HFIM, 03-
149.01 demonstrated a polymyxin B-dependent profile, where
more bacteria grew on agar containing polymyxin B than on drug-
free plates. The polymyxin dependence was most evident when the
high-exposure regimens (front-loading, burst, and supraburst)
FIG 2 Total population of ATCC 19606 in response to polymyxin B regimens
in the hollow-fiber infection model. The following regimens for polymyxin B
were simulated: regimen 1, polymyxin B non-loading dose (1.43 mg/kg q12h,
generating an fAUC0 –24 of 28.9 mg/liter · h across the first day and an fAUCss
of 35.9 mg · h/liter at steady state); regimen 2, polymyxin B with loading dose
(2.22 mg/kg for 1 dose followed by 1.43 mg/kg q12h starting 12 h later, with an
fAUC0 –24 of 35.9 mg · h/liter across each day); regimen 3, polymyxin B front-
loading dose (3.33 mg/kg for 1 dose followed by 1.43 mg/kg q12h starting 12 h
later, with an fAUC0 –24 of 48.2 mg · h/liter across the first day and an fAUCss of
35.9 mg · h/liter at steady state); regimen 4, polymyxin B burst (5.53 mg/kg for
1 dose followed by no subsequent doses, with an fAUC0 –24 of 60.4 mg · h/liter);
and regimen 5, polymyxin B supraburst (18.4 mg/kg for 1 dose followed by no
subsequent doses, fAUC0 –24 of 202.5 mg · h/liter).
FIG 3 Total population of 03-149.01 in response to polymyxin B regimens in
the hollow-fiber infection model. The following regimens for polymyxin B
were simulated: regimen 1, polymyxin B non-loading dose (1.43 mg/kg q12h,
generating an fAUC0 –24 of 28.9 mg/liter · h across the first day and an fAUCss
of 35.9 mg · h/liter at steady state); regimen 2, polymyxin B with loading dose
(2.22 mg/kg for 1 dose followed by 1.43 mg/kg q12h starting 12 h later, with an
fAUC0 –24 of 35.9 mg · h/liter across each day); regimen 3, polymyxin B front-
loading dose (3.33 mg/kg for 1 dose followed by 1.43 mg/kg q12h starting 12 h
later, fAUC0 –24 of 48.2 mg · h/liter across the first day and an fAUCss of 35.9
mg · h/liter at steady state); regimen 4, polymyxin B burst (5.53 mg/kg for 1
dose followed by no subsequent doses, fAUC0 –24 of 60.4 mg · h/liter); and
regimen 5, polymyxin B supraburst (18.4 mg/kg for 1 dose followed by no
subsequent doses, fAUC0 –24 of 202.5 mg · h/liter).
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were plated on polymyxin B-containing agar at 24 h, at which
point counts on agar plates containing 10 mg/liter polymyxin B
exceeded the counts on plates which contained no polymyxin (0
mg/liter), as shown in Fig. 6A. The magnitude of dependence rose
with increasing drug exposure. Front-loading, burst, and su-
praburst regimens displayed bacterial counts on drug-containing
plates (polymyxin B drug plates of 10 mg/liter) that were 1.65,
1.84, and 2.55 log10 CFU/ml higher than those on drug-free agar,
respectively. Although the polymyxin-dependent growth on the
48-h PAPs (Fig. 6B) was less substantial than that of the 24-h
PAPs, polymyxin B-dependent growth was also observed, as the
front-loading, burst, and supraburst regimens displayed 1.49,
1.32, and 1.00 log10 CFU/ml higher bacterial counts, respectively,
on drug-containing plates (polymyxin B drug plates of 10 mg/
liter) than on drug-free agar. The polymyxin dependence again
was observed at 72 h (Fig. 6C); however, from 96 h to 336 h (Fig.
6D and E), bacterial counts on drug-free versus drug-containing
agar were similar.
The PK/PD relationship based upon analyzing the benefit of
killing and cost of resistance in the clinical isolate 03-149.01 as it
relates to exposure (i.e., the regimens) is shown in Fig. 7. The log
ratio area approach for 24-h bacterial killing of the total popula-
tion and the 336-h resistant subpopulations growing on agar con-
taining 3, 4, 6, 8, and 10 mg/liter of polymyxin B were well char-
acterized by Hill-type mathematical models, with R2 values of
0.995 and 0.998, respectively. The respective parameter estimates
for the log ratio area approach for 24-h bacterial killing of the total
population and the 336-h resistant subpopulations were the fol-
lowing: Emax, 2.78 and4.72; EC50, 38.5 and 34.9; andH, 10.6 and
10.2. At initial exposures (i.e., fAUC0 –24) of 38.5 mg · h/liter,
increasing the polymyxin B fAUCs resulted in increased bacterial
killing while gradually amplifying the development of resistant
subpopulations. At the intersection point of 38.5 mg · h/liter of
polymyxin exposure, the amount of bacterial killing was equiva-
lent to the amount of resistance that was amplified. At high expo-
sures of38.5 mg · h/liter, the benefit of increased bacterial killing
was greatly exceeded by the cost of amplification of polymyxin
resistance until both phenomena plateaued at60 mg · h/liter.
DISCUSSION
The polymyxin antibiotics have become a last line of defense
against A. baumannii isolates that are resistant to traditional ther-
apies, including carbapenems (23, 24). Colistin methanesulfonate
(CMS) is an inactive and inefficient prodrug that is slowly and
incompletely converted to the active form of colistin (16). Poly-
myxin B does not suffer from these limitations, as it is adminis-
tered in its active form. Administering high-intensity polymyxin B
regimens during the first several hours may be highly beneficial
from a bacterial killing perspective. Therefore, in the current study
we utilized the HFIM to evaluate the impact of increasing the
initial dose of polymyxin B against a high bacterial density of A.
FIG 4 Complete time course of subpopulations of ATCC 19606 plated on polymyxin B-containing agar in response to polymyxin B regimens in the hollow-fiber
infection model. The following regimens for polymyxin B were simulated: polymyxin B non-loading dose (1.43 mg/kg q12h, generating an fAUC0 –24 of 28.9
mg · h/liter across the first day and an fAUCss of 35.9 mg · h/liter at steady state) (A); polymyxin B with loading dose (2.22 mg/kg for 1 dose followed by 1.43 mg/kg
q12h staring 12 h later, fAUC0 –24 of 35.9 mg · h/liter across each day) (B); polymyxin B front-loading dose (3.33 mg/kg for 1 dose followed by 1.43 mg/kg q12h
starting 12 h later, fAUC0 –24 of 48.2 mg · h/liter across the first day and an fAUCss of 35.9 mg · h/liter at steady state) (C); polymyxin B burst (5.53 mg/kg for 1
dose followed by no subsequent doses, fAUC0 –24 of 60.4 mg · h/liter) (D); polymyxin B supraburst (18.4 mg/kg for 1 dose followed by no subsequent doses,
fAUC0 –24 of 202.5 mg · h/liter) (E).
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baumannii. A number of observations emerged from the present
investigation.
First, we were unable to identify a regimen of polymyxin B that
eradicated A. baumannii at a high inoculum. It has been well es-
tablished that both polymyxin B and colistin are concentration-
dependent antibiotics, and the area under the curve/MIC ratio
(AUC/MIC) best correlates with their efficacy (25, 26). However,
the PK/PD relationship for polymyxin B as it relates to suppres-
sion of resistance is largely unknown. Specifically, it is unclear
whether higher exposures of polymyxin B could overcome resis-
tance. A number of antibiotics in the literature have demonstrated
an inverted U phenomenon, whereby resistant subpopulations
rose initially and then declined with increasing drug exposure un-
til reaching a threshold that prevented resistance (27, 28). For
polymyxin B, resistance amplification continued despite high
fAUC exposures. At polymyxin exposures beyond an fAUC0 –24 h
of 38.5 mg · h/liter, increasing the dose intensity resulted in con-
tinual escalation of resistance amplification. Somewhat to our sur-
prise, in our proof-of-concept HFIM arms, supratherapeutic ex-
posures of polymyxin B resulted in initial rapid bacterial killing
followed by the rapid development of resistance. Therefore, driv-
ing regimens toward complete eradication may be an important
endpoint for resistance suppression, and this may be possible only
for polymyxin B in combination with other antibiotics.
Second, there appears to be limited utility in using polymyxin
B monotherapy against high-density A. baumannii infections
(18). In a recent multicenter study, 94 of 105 (89.5%) patients who
were treated with intravenous CMS were diagnosed with bacterial
pneumonia (9). In these infections, the bacterial density of the
total population is remarkably high and, as a consequence, results
in a higher frequency of resistant mutants (19). Zaccard et al.
determined that a significant proportion of patients (26.1%) with
Gram-negative pneumonia have been shown to have a bacterial
burden higher than 3  107 in dilution-transformed colony
counts of bronchoalveolar lavage fluid (17, 29). Based upon this,
the bacterial inocula simulated in the HFIM were approximately
108 CFU/ml to mimic these clinical scenarios. Against these high
bacterial densities, commonly administered clinical maintenance
doses of polymyxin B resulted in stasis. Additionally, the rapid
bacterial killing demonstrated on day 1 was no longer seen on days
2 to 14, where the total population was primarily comprised of
cells that were completely resistant to polymyxin B. However, the
development of polymyxin resistance driven by drug selective
pressure may be even more difficult to observe in vivo. Neverthe-
less, 20 patients were identified with colistin-resistant A. bauman-
nii which occurred almost exclusively in CMS-treated patients
(13). Taken together, defining the impact of aggressive polymyxin
regimens in patients with A. baumannii pneumonia is complex, as
it also involves additional factors, such as virulence, granulocytes,
and the production of chemokines and cytokines (30–32).
Third, in the present study we determined that higher drug
exposures resulted in A. baumannii resistant subpopulations that
FIG 5 Complete time course of subpopulations of 03-149.01 A. baumannii plated on polymyxin B-containing agar in response to polymyxin B regimens in the
hollow-fiber infection model. The following regimens for polymyxin B were simulated: polymyxin B non-loading dose (1.43 mg/kg q12h, generating an
fAUC0 –24 of 28.9 mg · h/liter across the first day and an fAUCss of 35.9 mg · h/liter at steady state) (A); polymyxin B with a loading dose (2.22 mg/kg for 1 dose
followed by 1.43 mg/kg q12h starting 12 h later, fAUC0 –24 of 35.9 mg · h/liter across each day) (B); polymyxin B front-loading (3.33 mg/kg for 1 dose followed
by 1.43 mg/kg starting 12 h later, fAUC0 –24 of 48.2 mg · h/liter across the first day and an fAUCss of 35.9 mg · h/liter at steady state) (C); polymyxin B burst (5.53
mg/kg for 1 dose followed by no subsequent doses, fAUC0 –24 of 60.4 mg · h/liter) (D); polymyxin B supraburst (18.4 mg/kg for 1 dose followed by no subsequent
doses, fAUC0 –24 of 202.5 mg · h/liter) (E).
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demonstrated a dependence on polymyxin B for growth: the bac-
terial counts after 24 h of exposure to polymyxin B in the HFIM
were significantly higher on drug-containing agar than on drug-
free agar. Alterations of lipopolysaccharide in the development of
resistance have been proposed as a mechanism of colistin resis-
tance (33–36). Qureshi et al. recently determined that lipid A
modification by the addition of phosphoethanolamine was a pri-
mary mechanism for colistin resistance in colistin-resistant A.
baumannii isolates from patients with VAP (13). Moffatt et al.
previously determined that the complete loss of LPS is another
mechanism contributing to colistin resistance (35, 36). Recent
metabolomic studies determined that the development of resis-
tance in a lipopolysaccharide (LPS)-deficient, polymyxin-resis-
tant strain (19606R) was due to perturbation in specific amino
acid and carbohydrate metabolites, particularly pentose phos-
phate pathway and tricarboxylic acid cycle intermediates (36, 37).
Metabolomic and structural analyses of a polymyxin-resistant iso-
late, which emerged from the original 03-149-1 isolate (from the
current study), identified the modification of lipid A with phos-
phoethanolamine (37). Taken together with the potential for evo-
lution of resistance during polymyxin therapy in patients (13), the
dose intensity and extent of killing by the first dose of polymyxin B
also may play a role in driving these genomic and metabolomic
changes.
Finally, it is important to note the situations in which the par-
adoxical effect for polymyxin B may be relevant. The paradoxical
effect for polymyxin B may occur only in the context of a high
bacterial density under optimal growth conditions. At lower bac-
terial densities, high exposure of polymyxin B has been shown to
result in rapid bacterial killing and complete suppression of resis-
FIG 7 Cost-benefit PK/PD relationship for increasing polymyxin B exposure
against 03-149.01. Benefit (blue line) was defined as the initial bacterial killing of
the total population within the first 24 h. Cost (red line) was the amplification of
resistant subpopulations, which was based upon real-time PAP data over 336 h
that tracked A. baumannii growth on agar containing polymyxin B at 3, 4, 6, 8,
and 10 mg/liter. The intersecting fAUC for the drug exposure at which the
benefit of bacterial killing equaled the cost of resistance amplification was 38.5
mg · h/liter.
FIG 6 Real-time population analysis profiles (PAPs) for 03-149.01 comparing different dosing regimens at 24 h (A), 48 h (B), 72 h (C), 96 h (D), and 336 h (E).
Samples were quantified for total population by depositing appropriately diluted bacterial samples on MHA plates. Aliquots of the diluted sample were plated on
CAMHA plates containing polymyxin B at 0.5, 1, 2, 3, 4, 6, 8, or 10 mg/liter for an in-depth analysis of the time course of resistant subpopulations at the times
indicated in the panels (data for 144 h, 192 h, 240 h, and 288 h are not shown).
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tance (23, 36). The pharmacodynamics of polymyxin B will also
differ in patients with an intact immune system, owing to the
distinct relationship between granulocyte-mediated killing and
antibiotics (14). Nevertheless, the paradoxical effect for poly-
myxin B may also apply to other Gram-negative pathogens and
other polymyxin antibiotics such as colistin when given as a stand-
alone agent.
In conclusion, we observed a paradoxical effect whereby higher
polymyxin B exposures resulted in the increased amplification of
resistant, polymyxin B-dependent subpopulations. Therefore, the
utility of administering polymyxin B in a high-intensity fashion
may be restricted to aggressive combination regimens that combat
resistance amplification. Although increasing the dose of poly-
myxin B in combination regimens significantly improves bacterial
killing, the probability of nephrotoxicity increases as well (37–39).
Now, the challenge is to define optimal pharmaco- and toxicody-
namically driven regimens for polymyxin B combinations which
result in the greatest bacterial killing and suppression of resistance
and the least potential toxicity.
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